Ecolab Inc.

Ecolab Inc. (ECL) Market Cap

Ecolab Inc. has a market capitalization of .

No quote data available.

CEO: Christophe Beck

Sector: Basic Materials

Industry: Chemicals - Specialty

IPO Date: 1973-02-21

Website: https://www.ecolab.com

Ecolab Inc. (ECL) - Company Information

Market Cap: -|Sector: Basic Materials

Company Profile

Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through four segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences. The Global Water segment offers water treatment and process applications, and cleaning and sanitizing solutions to manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The Global Institutional & Specialty segment provides cleaning and sanitizing products to the foodservice, healthcare, hospitality, lodging, government, education and retail industries. The Global Pest Elimination segment provides pest elimination services to detect, prevent, and eliminate pests comprising rodents and insects in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations, and other commercial segments, including education, life sciences, and healthcare. The Global Life Sciences segment provides cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. It offers its products under the Ecolab, Kay, Purolite, and Bioquell brand names. The company sells its products through field sales and corporate account personnel, distributors, and dealers. Ecolab Inc. was founded in 1923 and is headquartered in Saint Paul, Minnesota.

Analyst Sentiment

77%
Strong Buy

From 28 Active Polls

1Y Forecast: $327.33

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$275

Median

$333

High Bound

$360

Average

$327

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$327.33
▲ +17.90% Upside
Low Target
$275.00
-1% Risk
Median Target
$332.50
20% Mid
High Target
$360.00
30% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ECOLAB INC (ECL) — Investment Overview

🧩 Business Model Overview

Ecolab supplies mission-critical chemicals, equipment, and application services used to manage hygiene, cleaning, and water treatment across food processing, healthcare, hospitality, industrial manufacturing, and institutional end-markets. The model combines (1) formulation and delivery of specialty products, (2) on-site and technical support to optimize chemistry and dosing, and (3) equipment integration that enables consistent outcomes (clean-in-place, disinfection, wastewater and water treatment performance).

Customer value is realized through reduced downtime and waste, improved compliance with sanitation standards, and more efficient water/energy use. Stickiness emerges because these programs are operationally embedded—tied to plant SOPs, equipment, training, and ongoing performance verification—making vendor changes costly and disruptive.

💰 Revenue Streams & Monetisation Model

Revenue is generated through a mix of:

  • Consumable chemical sales (transactional, but recurring in practice due to ongoing usage).
  • Equipment and program components that support dosing, monitoring, or treatment processes (typically lumpy and lower in share than consumables).
  • Services and application support, including on-site technical assistance, process optimization, and maintenance/program management (more recurring, with repeatable service demand).

Margin drivers generally include: (1) portfolio mix toward higher value specialty chemistries and services, (2) pricing discipline and product differentiation, and (3) operational leverage from manufacturing efficiency and field service productivity. Working-capital management and logistics execution also influence cash conversion due to the distribution intensity of chemical supply chains.

🧠 Competitive Advantages & Market Positioning

Ecolab’s moat is primarily rooted in switching costs and process/operational integration, reinforced by scale and technical know-how.

  • Switching Costs (Operational & Compliance-Driven): Sanitation and water treatment programs are implemented through standardized operating procedures, trained personnel, equipment settings, and documented performance. Changing vendors can require requalification, process resets, and production interruptions—raising effective switching barriers.
  • Technical Intangibles: Formulation expertise, application engineering, and operational troubleshooting build durable customer relationships. Competitors can sell products, but matching outcomes consistently at scale is harder.
  • Scale and Service Footprint: Broad manufacturing capability and field presence support reliable supply and faster issue resolution, which matters in regulated and uptime-sensitive environments.

Competitive benchmarking:

  • Diversey (and broader hygiene/cleaning portfolio providers): competes in cleaning and hygiene solutions, often with a similar equipment/chemical bundling approach. Ecolab’s distinction tends to be deeper application engineering integration and a broader industrial/water treatment platform across end-markets.
  • Veolia (water and wastewater treatment services): competes on large-scale treatment programs and infrastructure-adjacent services. Ecolab typically focuses on chemical solutions and operational performance within customer facilities, where dosing, compliance, and day-to-day execution create more frequent switching friction.
  • Xylem (water technologies): competes in water systems and monitoring technologies. Ecolab’s positioning emphasizes chemistry + application support + integration with customer operating systems, rather than primarily selling hardware-led solutions.

Across these rivals, Ecolab’s industry focus emphasizes embedded, outcomes-based programs for hygiene and water management rather than purely product or infrastructure-led offerings.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, Ecolab’s opportunity is supported by durable end-market needs and structural adoption of outsourcing and compliance-driven performance:

  • Water scarcity and efficiency: Customers seek lower water use, reduced wastewater load, and improved treatment performance—supporting sustained demand for optimized chemistry and treatment programs.
  • Hygiene and infection-control expectations: Higher sanitation standards in healthcare, food production, and hospitality drive recurring chemical and service consumption.
  • Regulatory compliance and documentation: Environmental and public health requirements increase the value of vendors that provide measurement, dosing guidance, and performance verification.
  • Industrial modernization and outsourcing: Many facilities prefer specialized chemical and application support to internalize expertise, creating recurring service-related spend.
  • Sustainability-linked optimization: Customers increasingly target reduction in chemical usage, energy, and waste; optimized programs can support both volume stability and selective pricing/mix improvements.

⚠ Risk Factors to Monitor

  • Input cost and logistics volatility: Specialty chemical supply chains can face cost swings, impacting margins if pass-through timing lags.
  • End-market cyclicality: Industrial activity and hospitality/food throughput can affect chemical volumes.
  • Regulatory and product liability: Increased scrutiny of chemical substances and sanitation practices can raise compliance costs and create litigation exposure.
  • Technology and formulation disruption: Shifts in disinfectant chemistry, filtration approaches, or treatment methodologies could pressure differentiation if competitors offer superior outcomes or cost structures.
  • Concentration and customer contracting dynamics: Large accounts may renegotiate pricing or shift programs, particularly when service differentiation is not perceived as value-accretive.
  • Execution risk in scale and capacity planning: Field service productivity, manufacturing reliability, and integration of portfolio changes are critical to sustaining margin and service quality.

📊 Valuation & Market View

Ecolab is typically valued as a quality industrial/consumer-adjacent services and specialty chemicals business, often anchored to EV/EBITDA and earnings power rather than pure asset value. Key valuation sensitivities include:

  • Quality of earnings: stability of recurring-like consumables and services vs. purely transactional exposure.
  • Margin structure: pricing discipline, service mix, and operational leverage that influence sustainable operating margins.
  • Cash conversion: working-capital management and capex intensity relative to earnings.
  • Growth durability: evidence of penetration and retention tied to operational outcomes, not just volume.

Because the business benefits from embedded customer programs, investors generally pay higher multiples when visibility into service continuity, pricing power, and margin resilience are credible.

🔍 Investment Takeaway

Ecolab’s long-term thesis rests on embedded switching costs created by integrated hygiene and water treatment programs, supported by application engineering capabilities and a broad service footprint. The competitive landscape is active, but replicating consistent outcomes and operational integration at customer sites is difficult—creating durable customer retention and supporting steady earnings power. Monitoring margin durability through input-cost cycles, regulatory exposure, and end-market demand remains central to underwriting the investment.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ECL reported Q1 2026 revenue of $4.07B, up 7.0% YoY (vs $3.70B in Q1 2025) and down 3.0% QoQ (vs $4.20B in Q4 2025). Net income was $432.6M, up 6.3% YoY (vs $402.5M in Q1 2025) but down 23.3% QoQ (vs $563.9M in Q4 2025). EPS was $1.53 vs $1.42 YoY (+7.7%) and below $2.00 QoQ (-23.5%). Profitability appears mixed: the net margin fell to 10.64% from 13.44% in Q4 2025, indicating margin compression QoQ, while remaining slightly below Q1 2025’s 10.89% (minor YoY softness). Operating income declined QoQ as well ($622.0M vs $785.9M). Cash flow quality is a relative bright spot: operating cash flow was $445.9M and free cash flow was $97.4M. This is down sharply QoQ in absolute terms versus Q4’s $758M free cash flow, but still supports dividends of $215.9M. Leverage remains meaningful with total debt of $9.10B and net debt of $8.58B, while equity was $10.03B. Total shareholder return is supported by a 1-year price change of +16.46% (not >20% momentum). With a very low dividend yield (~0.29%), most shareholder return is likely price-driven rather than income-driven. Analyst valuation context shows a consensus price target of 327.11 vs current price 274.8 (upside ~19%)."

Revenue Growth

Positive

Q1 2026 revenue grew +7.0% YoY but declined -3.0% QoQ, suggesting solid annual demand but softer sequential momentum.

Profitability

Neutral

Net margin contracted QoQ (10.64% vs 13.44%) while remaining roughly flat YoY (10.64% vs 10.89%). EPS rose +7.7% YoY but fell -23.5% QoQ.

Cash Flow Quality

Fair

Operating cash flow was $445.9M and free cash flow was $97.4M; both were materially lower QoQ. Dividends were paid ($215.9M), but FCF coverage weakened versus the prior quarter.

Leverage & Balance Sheet

Neutral

Total assets were $25.04B with equity of $10.03B. Leverage remains elevated (net debt ~$8.58B), though equity is broadly stable vs prior quarters.

Shareholder Returns

Neutral

1y price change is +16.46% (positive but below the >20% momentum threshold). Dividend yield is low (~0.29%), so total returns are likely mostly capital appreciation.

Analyst Sentiment & Valuation

Good

Consensus target is 327.11 vs price 274.8, implying ~19% upside. High-price multiples exist, but analyst outlook appears supportive.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Ecolab’s Q2 2026 showed broad-based acceleration, with Adjusted EPS up 11% alongside 5% organic sales growth, stable organic gross margins, and productivity gains. The key near-term swing factor was pricing: starting Q2 with minimal surcharge, management implemented a global energy surcharge with incremental customer value, lifting pricing to 4% and targeting 5%–6% in 2H to offset sustained commodity cost pressure. Portfolio mix continues shifting toward growth engines, led by Life Sciences (+15%) and Global High-Tech (+29%), the latter strengthened by CoolIT (closed July 2) and an integrated platform plan. Management increased 2026 EPS guidance to $8.05–$8.25 while reaffirming the 2027 20% operating income target despite CoolIT amortization impacts; the bridge highlighted lapping dynamics and offsetting Nalco amortization roll-offs next year. Analyst questions focused on margin offset mechanics, high-tech mix/trajectory to $4B by 2030, and life sciences driver sustainability tied to capacity expansion (including a major China plant).

AI IconGrowth Catalysts

  • Global energy surcharge implementation; pricing strengthened to 4% in Q2 and expected 5% to 6% in 2H (offset rising commodity costs)
  • Life sciences accelerating to 15% growth driven by bioprocessing + pharma/personal care share gains and improved purification performance
  • Ecolab Digital grew 27% with DishIQ, AquaIQ, KitchenIQ, and CIPIQ; continued expectation of >20% long-term Ecolab Digital growth
  • Pest Elimination delivered 7% growth driven by One Ecolab share gains and nearly 800,000 connected devices deployed; targeting 1 million by year-end
  • Global high-tech grew 29% (microelectronics + data centers) driven by AI infrastructure buildout; acquisition of CoolIT closed July 2

Business Development

  • Acquisition of CoolIT Systems closed July 2; CoolIT year-to-date sales growth prior to acquisition >100%
  • Integrated global high-tech platform built with Ovivo (microelectronics) and CoolIT (data center cooling); combined expectation to grow >25% annually
  • Investor Day planned at Supercomputing Chicago on November 17

AI IconFinancial Highlights

  • Adjusted EPS grew 11% with accelerating organic sales growth of 5%
  • Stable organic gross margin and continued strong productivity
  • Energy/commodity transition: started quarter with very little surcharge pricing; surcharge benefits progressively built through Q2; pricing 4% in Q2
  • 2H 2026 outlook: organic sales growth 6% to 7% and adjusted operating income margin 19% (supporting 20% OI margin next year)
  • Increased 2026 EPS guidance to $8.05 to $8.25 (up 7% to 10% vs last year) reflecting strong underlying performance plus short-term impact from noncash amortization/financing costs from CoolIT
  • 2027 commitment reaffirmed: 20% operating income target despite incremental CoolIT amortization; 2H 2027 expected to be stronger given lapping dynamics
  • Life sciences reported margin expectation: mid-20% operating income margin this quarter; underlying operating income margin expected mid-20s and reported margin in Q3 expected high-teens
  • Global high-tech pro forma note: on a pro forma basis including Ovivo and CoolIT, sales growth would have been ~7% in Q2 (incremental growth contribution)

AI IconCapital Funding

    AI IconStrategy & Ops

    • Global energy surcharge deployed with incremental customer value; target 5% to 6% benefit range for 2H
    • Connected platform build-out: nearly 800,000 pest-intelligence connected devices deployed; target 1 million by year-end; aim nearly 99% pest-free environments
    • High-tech platform integration plan: launch breakthrough integrated end-to-end cooling platform at Supercomputing combining CoolIT liquid cooling + Ecolab 3D TRASAR digital capabilities; CDU integration (3D TRASAR embedded into next-generation CDU within ~2 weeks)
    • Life sciences capacity/capability scaling: opening latest major plant in China (expand Asia footprint) and ongoing capacity build across North America and Europe; purification capacity constraints expected to ease with China plant
    • CapEx posture: invest ahead of growth in growth engines; company expects total CapEx as a % of sales to remain around ~7% for next couple of years while scaling global high-tech and life sciences

    AI IconMarket Outlook

    • 2H 2026: organic sales growth 6% to 7%; adjusted operating income margin 19%
    • 2026: EPS guidance $8.05 to $8.25
    • 2H 2027: expected to be stronger due to CoolIT acquisition lapping (CoolIT closed early July; comparisons mid-next year)
    • Global high-tech targets: platform expected to grow >25% annually; reach $4B sales by 2030 with operating income margin 25% (with pro forma trajectory acceleration; prior expectations referenced as >20% growth and 20% OI margin)
    • Investor Day: Supercomputing Chicago on November 17 (date specified)

    AI IconRisks & Headwinds

    • Customer operations disruption from conflict in the Middle East: volumes grew 1% despite nearly 1% headwind
    • Commodity cost increases expected to remain high through the year; risk of margin pressure partially offset by surcharge pricing
    • CoolIT acquisition accounting impacts: incremental noncash amortization and financing costs create short-term EPS drag vs underlying performance
    • Industry consolidation effects: paper business impacted by loss of paper mills; consolidation pause improving results but sensitivity remains
    • Life sciences margins influenced by timing/quarters: Q2 bioprocessing spike; margins can fluctuate quarter-to-quarter even with underlying trajectory

    Q&A: Analyst Interest

    • 2027 operating margin bridge and how CoolIT amortization is offset: Management reaffirmed 20% operating income in 2027 unchanged, citing the ongoing framework of 5%–7% organic growth to 20% OI margin and 12%–15% EPS growth; CFO added Nalco amortization falls off next year, offsetting CoolIT amortization timing.
    • Global high-tech growth visibility and $4B target confidence: Management said current high-tech annualized sales are ~ $1.5B, split roughly $500M each across legacy microelectronics/data centers plus Ovivo and CoolIT; legacy grew 29%, Ovivo mid-teens, CoolIT north of 100% initially, supporting a >25% trajectory to $4B by 2030.
    • Life sciences growth composition and sustainability versus capacity/investment: Management framed performance as outperforming market and competition while getting back in line with expected returns after earlier ramp delays; emphasized customer trust, capacity/capability build across North America/Europe/Asia, and a China plant addressing purification capacity constraints to sustain growth.

    Sentiment: POSITIVE

    Note: This summary was synthesized by AI from the ECL Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    Loading financial data and tables...
    © 2026 Stock Market Info — Ecolab Inc. (ECL) Financial Profile